Tedizolid Can Be Safely Used in Patients with Hepatitis Without Dose Adjustment
Yes, tedizolid can be given to patients with hepatitis, and no dose adjustments are required for any degree of hepatic impairment, including severe hepatic dysfunction (Child-Pugh Class C).
Pharmacokinetic Evidence in Hepatic Impairment
The FDA drug label provides definitive guidance on tedizolid use in hepatic impairment 1. Following a single 200 mg oral dose in patients with moderate (Child-Pugh B, n=8) or severe (Child-Pugh C, n=8) hepatic impairment, no clinically meaningful changes in tedizolid Cmax or AUC were observed compared to matched healthy controls 1.
Research data corroborate these findings, showing only minimal alterations in tedizolid pharmacokinetics with hepatic impairment 2:
- Moderate hepatic impairment: AUC increased approximately 22%
- Severe hepatic impairment: AUC increased approximately 34%
These modest increases are not considered clinically significant because:
- Tedizolid's elimination pathway is not primarily hepatic oxidative metabolism 1. The drug undergoes conjugation via sulfotransferase (SULT) isoforms rather than CYP450 enzymes, making it less susceptible to hepatic dysfunction
- The majority of elimination (82%) occurs via the liver through biliary excretion, but this pathway remains functional even in severe hepatic impairment 1
- Population pharmacokinetic analysis confirmed that measures of liver function do not clinically impact tedizolid pharmacokinetics 1
Clinical Safety Data
A pooled safety analysis of 1,280 participants receiving tedizolid 200 mg demonstrated comparable tolerability in patients with hepatic disease/impairment (n=294) versus the overall population 3. Drug-related adverse events occurred in only 27% of participants, with most being mild-to-moderate gastrointestinal reactions and headache.
One case report noted elevated tedizolid concentration (Cmin 1.01 μg/mL) in a patient with hepatic cirrhosis, though this was an isolated finding 4. The clinical significance remains unclear, as thrombocytopenia—the primary safety concern with oxazolidinones—occurred in patients with normal tedizolid concentrations in this study.
Practical Recommendations
- Standard dosing: Use tedizolid phosphate 200 mg once daily (oral or IV) for 6 days regardless of hepatic function status
- No monitoring required: Unlike some hepatically-cleared antibiotics, therapeutic drug monitoring is not routinely necessary for tedizolid in hepatic impairment
- Switching routes: No adjustment needed when transitioning between IV and oral administration, as bioavailability is approximately 91% 1
Important Caveat
While tedizolid itself requires no dose adjustment in hepatitis, be aware that tedizolid inhibits BCRP transporters and increases rosuvastatin exposure by 55-70% 1. If patients with hepatitis are on statins or other BCRP substrates, consider temporary discontinuation or close monitoring during tedizolid therapy.
This contrasts sharply with protease inhibitors used for hepatitis C treatment (e.g., paritaprevir, simeprevir, asunaprevir), which are contraindicated or not recommended in moderate-to-severe hepatic impairment due to significant drug accumulation 5, 6, 5, 6, 7.